Akribion Therapeutics

What Akribion Therapeutics does

Akribion Therapeutics GmbH is a pre-clinical biotechnology company founded in 2024 and headquartered in Zwingenberg, Germany, that was spun out of BRAIN Biotech AG to develop the proprietary G-dase® E platform — an RNA-guided nuclease enzyme-based technology for programmable cell depletion. Mechanistically, G-dase® E belongs to a new family of CRISPR nucleases with a unique mode of action: the enzyme remains inactive until it encounters a highly specific match between its loaded guide RNA and an intracellular RNA sequence, at which point it non-specifically degrades cellular DNA and RNA, killing the target cell. The technology is engineered for single-nucleotide specificity, and new cellular targets can be selected by exchanging only a short guide RNA, enabling rapid redirection across indications.

The company's lead therapeutic focus is precision oncology, with an initial indication in HPV-induced Oropharyngeal Head & Neck Cancer (OPSCC); the platform's flexibility is being explored for additional oncology indications as well as autoimmune diseases, fibrosis, and infectious diseases. The founding scientific team — including Co-Founders and Co-CEOs Dr. Michael Krohn and Lukas Linnig, and Co-Founder/Head of R&D Dr. Paul Scholz (the named inventor of G-dase® E) — was assembled primarily from the discovery group at parent BRAIN Biotech AG. The company exited stealth in February 2025 with an €8 million seed financing round led by CARMA FUND and RV Invest, with participation from High-Tech Gründerfonds, MP Beteiligungs GmbH, Hessen Kapital I, and Bruker Invest.

Akribion is pre-revenue and has no commercial products. Its expected revenue model is licensing, co-development partnerships, and eventual commercialization through pharmaceutical alliances or direct sales of approved therapeutics. As of the available data, the company's value creation will depend on demonstrating in vivo Proof of Concept with the seed funding, expanding the indication pipeline, and ultimately transacting platform-level partnerships with larger pharmaceutical counterparties.

Name

Akribion Therapeutics

Legal name

Akribion Therapeutics GmbH

Website

https://akribion-therapeutics.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Akribion Therapeutics is a pre-clinical German biotech developing G-dase® E, an RNA-guided nuclease platform for programmable cell depletion. Spun out of BRAIN Biotech AG in 2024, it initially targets HPV-induced oropharyngeal cancer, with broader oncology and disease applications.

Ownership category

akta.pro rank

Product category

Precision Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo) (HLAAACAD)

akta.pro secondary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

Keywords

• RNA-guided nuclease therapeutics
• Programmable cell depletion
• Precision oncology therapeutics
• CRISPR-based gene therapy
• Biopharmaceutical drug development

Headquarters

HQ city

Zwingenberg

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Therapeutic Development & Licensing: Pre-revenue biotech company developing novel RNA-guided cell depletion therapeutics. Revenue model will likely involve licensing of technology, co-development partnerships, and eventual product commercialization through pharmaceutical partnerships or direct sales.

Distribution channels1 record

Marketing channels3 records

Core offering

Akribion Therapeutics is developing G-dase® E, a proprietary RNA-guided nuclease enzyme-based technology platform for programmable cell depletion. The platform enables highly specific killing of targeted cells by shredding DNA and RNA only when a guide RNA matches an intracellular RNA sequence, with single-nucleotide precision. The company's initial therapeutic focus is HPV-induced Oropharyngeal Head & Neck Cancer (OPSCC), with broader applications being explored in precision oncology, autoimmune diseases, fibrosis, and infectious diseases.

Product overview

Akribion Therapeutics is developing G-dase® E, a proprietary RNA-guided nuclease-based technology platform for programmable cell depletion. The technology allows very specific depletion of certain subsets of cells based on the presence of a predetermined RNA sequence. The company is initially focused on advancing precision oncology therapies targeting HPV-induced Oropharyngeal Head & Neck Cancer (OPSCC), while also exploring applications in additional oncology indications, autoimmune diseases, fibrosis, and infectious diseases.

Differentiator

Problem solved

Functional benefit

Brands

• G-dase E: RNA-guided, nuclease-based technology for programmable cell depletion that can kill cells by shredding DNA and RNA when there is a specific match between guide RNA and intracellular RNA sequence.

Products and services

• G-dase® E Technology Platform A unique RNA-guided nuclease enzyme-based technology platform for programmable cell depletion. Belongs to a new family of CRISPR nucleases with a unique mode of action that has been optimized for strong potency and specificity in human cells. The nuclease kills cells by shredding DNA and RNA only when there is a highly specific match between guide RNA and an intracellular RNA sequence. Initially targeting HPV-induced Oropharyngeal Head & Neck Cancer (OPSCC) with applications across precision oncology, autoimmune diseases, fibrosis, and infectious diseases.

Quantifiable outcome

• Up to single nucleotide specificity in cell targeting
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core and minor.

• BRAIN Biotech AGcoreStrategic or Co-development Partner · 4 February 2025Parent company from which Akribion was spun out in 2024. The G-dase® E technology was discovered by Dr. Paul Scholz and team at BRAIN Biotech. Co-Founders Michael Krohn and Lukas Linnig held positions there.
• Volnay TherapeuticsminorStrategic or Co-development PartnerBoston-based cell and gene therapy investor and incubator where Board Chair Adel Nada serves as venture partner.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/akribion-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Akribion Therapeutics